Provided by Tiger Fintech (Singapore) Pte. Ltd.

Taysha Gene Therapies, Inc.

1.45
+0.210016.94%
Post-market: 1.480.0294+2.03%19:59 EDT
Volume:4.66M
Turnover:6.58M
Market Cap:297.25M
PE:-4.06
High:1.48
Open:1.23
Low:1.22
Close:1.24
Loading ...

Company Profile

Company Name:
Taysha Gene Therapies, Inc.
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
73
Office Location:
3000 Pegasus Park Drive,Suite 1430,Dallas,Texas,United States
Zip Code:
75247
Fax:
- -
Introduction:
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Directors

Name
Position
Sean P. Nolan
Chief Executive Officer and Chairman of Board
Sukumar Nagendran
Director and President and Head of Research and Development
Kathleen Reape
Director
Laura Sepp Lorenzino
Director
Paul B. Manning
Director
Phillip B. Donenberg
Director

Shareholders

Name
Position
Sean P. Nolan
Chief Executive Officer and Chairman of Board
Kamran Alam
Chief Financial Officer
Sukumar Nagendran
Director and President and Head of Research and Development